Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
2Customers
2Debt Items
3Related Chains
Source-Backed Evidence Depth
Alaunos Therapeutics, Inc. (TCRT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
11High confidence
0.868Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Alaunos Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
THE-UNIVERSITY-OF-TEXAS-M-D-ANDERSON-CANCER-CENT
THE-UNIVERSITY-OF-TEXAS-M-D-ANDERSON-CANCER-CENT
92%
Under the Settlement Agreement, the Company agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding invoices
ARES-TRADING-S-A
ARES-TRADING-S-A
90%
10.10† License and Collaboration Agreement by and among the Registrant, Intrexon Corporation and Ares Trading S.A. dated as of March 27, 2015
INTREXON-CORPORATION
INTREXON-CORPORATION
90%
10.6# License Agreement by and among the Registrant, Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as…
NATIONAL-CANCER-INSTITUTE
NATIONAL-CANCER-INSTITUTE
90%
10.18# Patent License Agreement, dated as of May 28, 2019, by and between the Registrant and the National Cancer Institute
PGEN-THERAPEUTICS-INC
PGEN-THERAPEUTICS-INC
90%
10.8# Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020
PRECIGEN-INC
PRECIGEN-INC
90%
10.7† Exclusive License Agreement by and between the Registrant, Precigen, Inc. and Intrexon Corporation, dated October 5, 2018
THE-UNIVERSITY-OF-TEXAS-SYSTEM-BOARD-OF-REGENTS
THE-UNIVERSITY-OF-TEXAS-SYSTEM-BOARD-OF-REGENTS
90%
10.6# License Agreement by and among the Registrant, Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as…
Reciprocal relationship from TIVC graph: for the treatment of ARS. Furthermore, the Company holds Investigational New Drug ("IND") applications for Entolimod in both ARS and advanced oncology, with p…
Alaunos Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
SOLASIA-PHARMA-K-K
SOLASIA-PHARMA-K-K
92%
As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentag…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
hs ended March 31, 2026 and 2025 were as follows: For the Three Months Ended March 31, 2026 2025 Change ($ in thousands) General and administrative expenses $ 585 $ 747 $ (162 ) (22 )% General and ad…
Alaunos Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TCRT-DEBT-12916
Warrants outstanding: 18939394
90%
xbrl warrant detail from xbrl 2026-03-31.
TCRT-DEBT-12917
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2014-12-31.
Alaunos Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Alaunos Therapeutics, Inc..
Alaunos Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
TCRT-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 30 tracked holders.
Alaunos Therapeutics, Inc. Extended Supply Chain Network
